JCSE01.06 New Era Beyond PD-1/PD-L1

Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1

The histiocytoses are rare tumors characterized by the primary accumulation and tissue infiltration of histiocytes and dendritic cells. Identification of the activating BRAFV600E mutation in Erdheim-Chester disease (ECD) and Langerhans cell histiocytosis (LCH) cases provided the basis for the treatment with BRAF and/or MEK inhibitors, but additional treatment options are needed. Twenty-four cas...

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade

Immune checkpoint blockades, such as inhibitors against programmed death 1 (PD-1) and its ligand (PD-L1), have received extensive attention in the past decade because of their dramatic clinical outcomes in advanced malignancies. However, both primary and acquired resistance becomes one of the major obstacles, which greatly limits the long-lasting effects and wide application of PD-1/PD-L1 block...

Macrophage PD-L1 strikes back: PD-1/PD-L1 interaction drives macrophages toward regulatory subsets

Activated macrophages have been simply defined as cells that secrete inflammatory mediators and kill intracellular pathogens until few years ago. Recent studies have proposed a new classification system to separate activated macrophages based on their functional phenotypes: host defense, wound healing, and immune regulation. Regulatory macrophages can arise following innate or adaptive immune r...

Over-Expression of Immunosuppressive Molecules, PD-L1 and PD-L2, in Ulcerative Colitis Patients

PD-L1, Inflammation and Glioblastoma

The PD-L1 protein has an extracellular domain, a transmembrane domain and an intracellular domain. The extracellular domain (ECD) of the PD-L1 protein is comprised of IgC–like and IgV-like domains [2]. The ECD of PD-L1 interacts with the programmed death 1 (PD-1, also known as PDCD1) and B7.1 receptors. Blocking of the PD-L1 molecule with antibodies blocks cancer cells from killing cytotoxic T ...